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ABSTRACT
Background: Thymus and activation-regulated chemokine (TARCCCL17) is a highly specific ligand for CCR
4. TARC may contribute to the recruitment , activation , and development of Th2 polarized cells that ex-
press CCR4. These characteristics have led investigators to hypothesize that TARC is involved in the develop-
ment of Th2 responses. Suplatast tosilate ((±)-[2-[4-(3-ethoxy-2-hydroxy-propoxy) phenylcarbamoyl] ethyl] di-
methylsulfonium p-toluenesulfonate) is an anti-allergic agent that selectively suppresses the synthesis of Th2
cytokines. We examined the effect of suplatast tosilate on TARC production and CCR-4 expression in vitro.
Furthermore, we attempted to clarify whether TARC production was suppressed after clinical administration of
suplatast tosilate.
Methods: Peripheral blood mononuclear cells (PBMCs) were isolated from patients with allergic rhinitis who
tested positive to house dust. PBMCs were stimulated with mite antigen. TARC mRNA was detected by real
time PCR. The amount of TARC was estimated using an ELISA kit. PBMCs expressing CCR-4 were sorted by
flow cytometry. The plasma level of TARC was examined in patients with chronic allergic rhinitis before and af-
ter treatment with suplatast tosilate for 4 weeks.
Results: Suplatast tosilate significantly reduced TARC production by PBMCs. TARC mRNA was also sup-
pressed in a concentration dependent manner. However, suplatast tosilate did not inhibit the expression of
CCR-4 on PBMCs. The plasma level of TARC was significantly decreased in patients administered suplatast
tosilate.
Conclusions: Suplatast tosilate suppressed TARC production by PBMCs and decreased the plasma level of
TARC in patients with chronic allergic rhinitis.
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INTRODUCTION
Allergic rhinitis, as asthma and atopic dermatitis, is a
manifestation of atopy characterized by the formation
of IgE in response to environmental allergens .
Eosinophils play an important role in the develop-
ment of swelling and hyperreactivity of the nasal mu-
cosa in response to non-specific stimulation.1-3 Anti-
gen presentation to Th2 memory cells leads to the
generation of interleukins ( IL ) -4, IL-13 and IL-5,
which are involved in the stimulation of IgE produc-
tion and the recruitment, activation and maintenance
of eosinophils . They also stimulate the release of
growth factors and chemokines from structural cells,
such as epithelial cells , endothelial cells and fibro-
blasts . It has been reported that lymphocytic cell
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lines derived from Th1 cells selectively express
CXCR3 and CCR5 in vitro, whereas lymphocytic cell
lines derived from Th 2 cells selectively express
CCR3,CCR4 and CCR8. 4-7 Thymus and activation-
regulated chemokine (TARC) was recently found to
be a highly specific ligand for CCR4.8 A number of
cellular sources of TARC have been identified, includ-
ing macrophages, dendritic cells, and natural killer
cells. In addition, CD4 positive T cells, including na-
ive T cells, Th2 cells and memoryeffector T cells,
were shown to produce TARC protein.9-11 They may
aid in the recruitment, activation, and development of
Th2 polarized cells that express CCR4. These charac-
teristics have led investigators to hypothesize that
TARC is involved in the development of the Th2 re-
sponse.12 Therefore, the interaction between TARC
and CCR4 is important in the pathogenesis of allergic
inflammation. In a basic study, suplatast tosilate ((±)-
[2-[4-(3-ethoxy-2-hydroxy- propoxy) phenylcarbamoyl]
ethyl]dimethylsulfoniump-toluenesulfonate) inhibited an
experimental asthma model of type I allergic reac-
tion, passive cutaneous anaphylaxis and allergic rhini-
tis. Furthermore, Suplatast tosilate was confirmed to
inhibit IgE antibody production in a class-specific
manner without inhibiting IgE and IgG antibody pro-
duction and to inhibit tissue infiltration by eosino-
phils, which is a cause of allergic inflammation. These
actions are considered to be based on the inhibition
of cytokine IL-4 and IL-5 produced by helper cells.13-
20 It also inhibits the allergen-induced increase of
both eosinophils and CD4+ T cells in airways and pre-
vents allergen-induced goblet cell metaplasia . 18,21
These results strongly suggest that suplatast tosilate
is a highly functional anti-allergic agent. In this study,
we examined the effect of suplatast tosilate on TARC
production from peripheral blood mononuclear cells
(PBMCs) and CCR-4 expression in vitro and in vivo.
METHODS
EFFECTS OF SUPLATAST TOSILATE ON THE
PRODUCTION OF TARC IN PBMCS
Subjects
This study enrolled 8 subjects with allergic rhinitis (6
men and 2 women, age 19―45 years, average age 25.2
± 6.9 years) and 8 healthy controls (3 men and 5
women , age 18―41 years , average age 24.6 ± 7.7
years). All subjects underwent measurement of total
serum IgE levels (IUml) and specific IgE antibody
levels (UAml) to at least six inhalant allergens in-
cluding house dust ( HD;Greer Labs, Lenoir , NC,
USA), mite (Dermatophagoides pteronyssinus), pollen
of Japanese cedar (Cryptomeria japonica), common
ragweed (Ambrosia artemisiifolia), cocksfoot (Dac-
tylis glomerata), and mugwort (Artemisia vulgaris) by
radioallergosorbent test (RAST). All patients with al-
lergic rhinitis had a score of 2 or more on a RAST to
Dermatophagoides farinae and a history of reasonably
recurrent sneezing, watery rhinorrhea, and nasal ob-
struction. Neither patients nor controls had used any
topical steroid or other medication for at least one
month before the study. The control individuals were
selected from among those who met the following
conditions:absence of eosinophilia in nasal smears ;
RAST negative to the six allergens;IgE not higher
than 300 Uml ; and absence of symptoms of nasal
hyper-reactivity, such as sneezing and watery nasal
discharge．
All patients were informed about the content of the
study, and gave informed consent prior to participa-
tion. In addition this study was approved by the eth-
ics committee of the Graduate School of Medicine,
Chiba University.
Cells
PBMCs were purified by centrifugation at 88 g for 30
min at 20℃ against a Ficoll-Hypaque density gradi-
ent. The cells at the interface (mononuclear cells)
were collected and washed twice in RPMI 1640 sup-
plemented with heat-inactivated 10% fetal calf serum
(FCS). We selected only mononuclear cells with a vi-
ability of more than 95% as assessed by the trypan
blue exclusion dye test . These mononuclear cells
were suspended in RPMI 1640 containing 10% FCS
and adjusted to a cell density of 2.5 × 105 cellsml.
They were incubated in the presence or absence of
suplatast tosilate at various concentrations for 24
hours, followed by challenge with mite antigen (10
μgml) for up to 96 hours. As a control, PBMCs, iso-
lated from healthy control subjects, were stimulated
with or without mite antigen . The effect of dex-
amethasone on TARC production was also examined.
The supernatants were separated by centrifugation at
200 g for 5 min at 4℃ and stored at −80℃ until use.
Cells were harvested and immediately frozen in liq-
uid nitrogen until use．
Real Time RT-PCR
Total RNA was extracted using an RNeasy kit
(Qiagen, Hilden, Germany) according to the manu-
facturer’s instructions. RNA concentration and purity
were determined on a spectrophotometer (UV-1201,
Shimadzu, Japan) by calculating the ratio of optical
density at wavelengths of 260 and 280 nm. An Omnis-
cript RT (Qiagen), a reverse transcriptase inhibitor
(Lifetech , Rockville , MD, USA) and an Oligo dT
primer (Lifetech) were used in the synthesis of com-
plementary DNA．
PCR was performed using a Light Cycler Fast Start
Hybridization Probes buffer (Roche Molecular Bio-
chemicals)22,23 by rapid cycling in a reaction volume
of 20 μl with 0.5 mmolL of each primer, 0.2 mmolL
of anchor probes, 0.4 mmolL of detection probes
and 50 ng of genomic DNA.
The Light Cycler Fast Start DNA Master Hybridi-
zation Probes buffer used was a 10-fold stock solution
containing nucleotides, Thermus aquaticus DNA po-
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Table 1 Oligonucleotides used in this sudy.
Sequence 5’ ―3’b-actin 459bp
CCAACCGCGAGCAGCTG Forward primer
GGAAGGAAGGCTGGAAG Reverse primer
CCTCCCCCATGCCATCCTGCGTC-FL Anchor probe
LC-GGACCTGGCTGGCCGGGACCTG Detection probe
TARC 241bp
TCTCTGCAGCACATCCACGC Forward primer
GGCTTCAAGACCTCTCAAGG Reverse primer
GCTCCAGGGATGCCATCGTT-FL Anchor probe
LC-TTGTAACTGTGCAGGGCAGGG Detection probe
lymerase and 10 mmolL of Mg2+. The final Mg2+
concentration in the reaction mixture was adjusted to
2 mmolL for TARC and 3 mmolL for β-actin. The
samples were loaded into glass capillary cuvettes
(Roche Molecular Biochemicals) and centrifuged to
place the sample at the capillary tip before capping.
After the initial denaturation at 95℃ for 10 min, DNA
was amplified through 40 cycles of denaturation
(95℃ for 15 sec ), annealing (60℃ for 15 sec) and
extension (72℃ for 10 sec). The temperature was
programmed to decrease 20℃ from denaturation to
annealing, 20℃ from annealing to extension, and 20
℃ from extension to denaturation. Fluorescence was
measured at the end of the annealing period of each
cycle to monitor amplification．
To detect TARC mRNA, four oligonucleotides were
used in the assay ; of them, two were the labeled an-
chor and detection probes and two served as amplifi-
cation primers (Table 1).
All the hybridization probe PCR assays were per-
formed in quadruplicate. The intraassay and interas-
say variation were 5.4% and 10.3%, respectively. The
ratio of TARC mRNA to β-actin mRNA was deter-
mined．
ELISA for TARC
The amount of TARC was estimated using an ELISA
kit (R & D Systems , Minneapolis , USA) and ex-
pressed in pgmL; the lowest detection limit was 7 pg
mL. The ELISA used did not cross-react with other
cytokines [IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8,
IL-10, IL-13, GM-CSF, IFN-γ and TNF-α] at levels of
50 ngmL.
Flow Cytometric Analysis of CCR-4 Expression
on PBMCs
In order to investigate the effect of suplatast tosilate
on CCR-4 expression, we examined the expression of
CCR-4 on PBMCs expressing CD4 or CD45RO be-
fore and after the clinical administration of suplatast
tosilate. The cells were stained with PE-conjugated
anti-CD4 monoclonal antibody (MoAb)(mouse IgG1,
R & D Systems) or cyanine dye-conjugated anti-CD45
RO MoAb (mouse IgG1, R & D Systems) followed by
FITC-conjugated anti-CCR4 (KM-2160, mouse IgG1).
This MoAb against CCR4 has been characterized in a
previous report.12 CCR-4 expression on CD4+CD45
RO+, CD4+CD45RO−, CD4−CD45RO+, or CD4−CD45
RO− PBMCs was examined.
The number of CCR-4+ PBMCs expressing CD4+
CD45RO+ was counted. Labeled cells were analyzed
using flow cytometry (FACScan, Becton-Dickinson,
San Jose, CA, USA)．
CHANGES IN TARC PLASMA LEVEL AFTER
CLINICAL ADMINISTRATION OF SUPLATAST
TOSILATE
The study was carried out on a group of 12 patients
sensitized to house dust mites and with symptoms of
perennial allergic rhinitis (7 men and 5 women, age
20―48 years, average age 28.6 ± 6.1 years). All pa-
tients had a score of 2 or more on a RAST to Derma-
tophagoides farinae. By using a patient diary, the se-
verity of nasal symptoms, such as sneezing, rhinor-
rhea and nasal obstruction, was scored by patients
each day during the study period in accordance with
the Severity Classification of the Clinical Practice
Guideline for Nasal Allergy and the Symptom Score
(Table 2). 24 Symptom scores were determined by
comparing the two different symptoms (Table 3). All
patients had a score of 2 or more on this symptom
score.
After a 1-week washout period, patients took oral
suplatast tosilate (100 mg, three times per day) for 4
weeks . Before and after the administration , the
plasma level of TARC was measured. The global im-
provement rating of“remarkably improved”was as-
signed when the symptom score decreased by 2
points or more. A rating of“moderately improved”
was assigned when the symptom score decreased by
1 point. General laboratory tests (hematology, bio-
chemical profile and urinalysis) were performed be-
fore and after treatment , in addition to monitoring
subjective and objective adverse reactions . It has
been reported that the adverse reactions of suplatast
tosilate appeared in 5.0% (731460) of the patients.25
Major adverse reactions included gastrointestinal
symptoms such as stomach discomfort (0.5%) and
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Fig. 1　Time-course of TARC production by PBMCs after 
stimulation with mite antigen. Data are the mean + SEM of 
four experiments. 
pg/ml
(hr)
0
50
100
150
0 24 48 72 96
PBS
Mite
Table 2 Evaluation criteria for determination of the symptom score
Score (points)
01234
05―110―620―11≧ 21Snoezing atacks＊
05―110―620―11≧ 21Nasal discharge†
No nasal
obstruction
No breathing 
through　the 
mouth, but na-
sal obstruction 
present
Nasal obstruction 
marked and breath-
ing thorough the 
mouth performed 
several timed a day
Nasal obstruction se-
vere and breathing 
through the mouth 
performed for a con-
siderable time
Complete nasal 
obstruction al 
day
Nasal obstruction
＊Mean no. atacks per day
†Mean no. nose blows per day
Table 3 Symptom score
Sneezing atack or secretion score
01234
Nasal obstruction score
444444
333343
222342
112341
012340
nausea (0.8%), hepatic function disorders such as in-
creased ALT (GPT)(0.4%) and increased AST (GOT)
(0.3%), sleepiness (0.6%), and rash (0.4%). All patients
were informed about the content of the study, and
gave informed consent prior to participation. In addi-
tion this study was approved by the ethics committee
of the Graduate School of Medicine, Chiba Univer-
sity．
Statistical Analysis
The results of the study were expressed as the mean
values ± SEM. Significance was determined using
paired Wilcoxon tests. A p value of <0.05 was consid-
ered to indicate a significant difference. The statisti-
cal software package SAS (SAS Institute Inc., Cary,
NC, USA) was used for the statistical analysis．
RESULTS
PBMCs were pre-incubated with suplatast tosilate
(10−5 to 10−8 M) or dexamethasone (10−7 M) for 24
hr and were then stimulated with mite antigen to in-
vestigate the effect of suplatast tosilate on the produc-
tion of TARC from these stimulated PBMCs . As
shown in Figure 1, mite antigen induced TARC pro-
duction by PBMCs, isolated from patients with aller-
gic rhinitis , in a time dependent manner . PBMCs
from healthy control subjects did not produce signifi-
cant amounts of TARC (data not shown). Dexametha-
sone (10−7 M) significantly inhibited the production
of TARC (Fig. 2). Pre-incubation with suplatast tosi-
late also decreased TARC production in a
concentration-dependent manner . At concentrations
of 1 × 10−5 and 1 × 10−6 M, suplatast tosilate signifi-
cantly reduced TARC production. Suplatast tosilate
did not affect TARC production by unstimulated
PBMCs (data not shown). The mRNA expression of
TARC was suppressed by suplatast tosilate in a
concentration-dependent manner (Fig. 3).
The effect of suplatast tosilate on the expression of
CCR-4 on PBMCs was clarified by treating the cells
with suplatast tosilate for 24 hr and examining the
change in CCR-4 expression by flow cytometry．
CCR 4 is preferentially expressed on CD4+CD
45RO+ PBMCs in patients with nasal allergy . The
mite antigen significantly upregulated CCR4 expres-
sion on PBMCs. However, suplatast tosilate did not
exhibit a significant concentration-dependent inhibi-
tory effect on the expression of CCR-4 on PBMCs at
concentrations of 1 × 10−5, 1 × 10−6 and 1 × 10−7 M (
Fig. 4).
Next, we attempted to clarify whether the produc-
tion of TARC was suppressed after clinical admini-
stration of suplatast tosilate. Based on the records in
an allergic symptom diary, the frequency of sneezing,
frequency of nose blowing and nasal obstruction
score were calculated for each patient in accordance
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Fig. 2　Efect of suplatast tosilate on TARC production by 
PBMCs. The supernatants were obtained 96 hr after stimula-
tion with mite antigen. Suplatast tosilate significantly re-
duced TARC production at concentrations of 1 × 10-5 and 
1 × 10-6 M. Data are the mean + SEM of eight experiments.
＊p < 0.05, † p < 0.01
PBS Mite Dexamethasone
10-7 M
+Mite
10-5 M 10-6 M 10-7 M 10-8 M
suplatast tosilate
+Mite
pg/ml
200
100
0
＊＊
＊
＊
＊
Fig. 3　Efect of suplatast tosilate on TARC mRNA expres-
sion in PBMCs. mRNA expression was normalized relative 
to that of β-actin mRNA. PBMCs were obtained 12 hr after 
specific antigen stimulation. Suplatast tosilate significantly 
reduced TARC mRNA expression at concentrations of 1 × 
10-5 and 1 × 10-6 M. ＊p < 0.05
 TARC mRNA/β actin mRNA 
1
2
0
＊
＊
＊
＊
PBS Mite Dexamethasone
10-7 M
+Mite
10-5 M 10-6 M 10-7 M 10-8 M
suplatast tosilate
+Mite
Fig. 4　Efect of suplatast tosilate on the expression of 
CCR-4 on PBMCs. Suplatast tosilate did not exhibit a signifi-
cant inhibitory efect on the expression of CCR-4 on 
PBMCs. ＊ p < 0.05, compared with the values of the mite 
control.
＊
20
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0
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PBS Mite 10-5 M 10-6 M 10-7 M
suplatast tosilate
with the Severity Classification of the Clinical Prac-
tice Guideline for Nasal Allergy and the Symptom
Score (Table 2). 24 After the start of the 4-week
suplatast tosilate treatment, all clinical scores, particu-
larly that of nasal obstruction, were significantly de-
creased (Fig . 5). More than two nasal obstruction
scores were decreased in 6 out of 12 patients
(Fig. 5c). According to a global improvement rating 3
patients were rated as“remarkably improved”，5 as
“moderately improved”，and 4 patients were rated as
“unchanged”．No subjectiveobjective adverse reac-
tions or abnormal changes in laboratory test results
were observed in any of the 12 patients treated with
suplatast tosilate for 4 weeks．
The plasma level of TARC was significantly de-
creased after the 4-week administration (Fig. 6). The
correlation between plasma TARC concentration and
these clinical parameters was tested. The percentage
of decrease in plasma TARC concentration was sig-
nificantly higher in the patients for whom suplatast
tosilate proved more than‘moderately improved’
(Fig. 7).
DISCUSSION
Suplatast tosilate is effective to control allergic dis-
eases such as allergic rhinitis . Many authors have
discussed the selective inhibitory effect of suplatast
tosilate on IgE and Th2 cytokine production.13-20 Al-
lergic rhinitis is characterized by inflammatory cell
infiltration, especially by eosinophils. It is probable
that suplatast tosilate attenuates the PAF- and
leukotriene-induced increase of edema and vascular
permeability by reducing this eosinophilic infiltration
of the nasal mucosa. This is possible because both IL-
4 and IL-5 are implicated in the pathogenesis of
eosinophilic inflammation 26-28 and because eosino-
phils are one of the major sources of PAF and leukot-
riene.29,30
In this study, we showed that suplatast tosilate in-
hibits TARC production by PBMCs stimulated with
mite antigen and that the plasma TARC concentration
decreased significantly in patients with chronic aller-
gic rhinitis after 4-week administration of suplatast to-
silate. These findings confirm the results of an earlier
study showing that suplatast tosilate inhibited TARC
production by antigen-specific human Th2 cells . 31
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Fig. 5　Efect of suplatast tosilate on nasal symptoms. 
Changes in symptom score of (A) Sneezing, (B) Rhinorhea, 
(C) Nasal obstruction. ＊p < 0.05
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Fig. 6　Efect of oral suplatast tosilate on the plasma level 
of TARC. The plasma level of TARC was significantly de-
creased after the 4-week administration. ＊P < 0.05
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Fig. 7　Comparison of changes in the plasma level of 
TARC between patients in whom suplatast tosilate was ef-
fective and those in whom it was not efective. ＊P < 0.05
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The expression of TARC in the bronchial epithelium
and sputum was significantly increased in asthmat-
ics. 32,33 Recently , we demonstrated that combined
stimulation with IL-4 and TNF-α, as well as with IL-13
and TNF-α, synergistically induced TARC expression
in epithelial cells. Furthermore, the amount of TARC
induced by these cytokines was higher in epithelial
cells obtained from patients with nasal allergy than in
patients without allergy.27 In addition, recent studies
have demonstrated that in patients with allergic dis-
eases CCR4 expression on peripheral blood CD4+T
cells and serum TARC levels correlated with the se-
verity of the disease. 34,35 Wakugawa et al. reported
that in patients with atopic dermatitis (AD) CCR4 ex-
pression on peripheral blood CD4+T cells was signifi-
cantly higher than in healthy subjects . Moreover ,
they observed that the symptoms improved with in-
tensive topical corticosteroid therapy and that CCR4
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expression on CD4+T cells gradually decreased as
the symptoms improved.34 Kakinuma et al. quantified
serum TARC levels in patients with AD, and exam-
ined the correlation between TARC levels and dis-
ease activity.35 The serum TARC level correlated with
the severity of the disease and the number of eosino-
phils in peripheral blood. Both the serum TARC level
and the number of eosinophils in peripheral blood de-
creased during treatment with topical corticosteroids
and oral antihistaminics, and those changes were as-
sociated with an improvement of the skin conditions.
Suplatast tosilate inhibited TARC production at a
concentration of 1 × 10-6 M, but showed no inhibitory
effect at 1 × 10-7 M, the serum level attained following
administration of the usual clinical dose. It appears
that suplatast tosilate exhibits an inhibitory effect
when it remains in contact with blood and tissues for
a prolonged period. It may be necessary to increase
its blood level to attain an appropriate inhibitory ef-
fect on TARC production induced by a specific anti-
gen.
Next, we attempted to clarify whether the produc-
tion of TARC was suppressed in patients with chronic
allergic rhinitis after treatment with suplatast tosilate.
As a result , the plasma TARC concentration de-
creased significantly after 4 weeks on suplatast tosi-
late . The percentage of decrease in plasma TARC
concentration was significantly higher in the patients
for whom suplatast tosilate was effective. In a previ-
ous study, we reported that compared with normal
subjects, the plasma TARC concentration was signifi-
cantly higher in patients with bronchial asthma ,
atopic dermatitis and allergic rhinitis.36 Another study
on the correlation between plasma TARC concentra-
tion and severity of clinical symptoms revealed that
plasma TARC concentration was significantly higher
in patients with severe allergic rhinitis than in those
with mild or moderate allergic rhinitis (Terada et al.
Unpublished data). The above findings suggest that
TARC plays a crucial role in the pathogenesis and de-
velopment of allergic rhinitis. Plasma TARC concen-
tration is an important index of the severity of allergic
rhinitis . Our present findings also suggest that
suplatast tosilate suppresses the production of TARC
and improves clinical symptoms of allergic rhinitis．
In conclusion, suplatast tosilate suppressed TARC
production by PBMCs and decreased the plasma
level of TARC after clinical administration. In addi-
tion, the percentage of decrease in plasma TARC con-
centration was significantly higher in patients who re-
sponded to treatment with suplatast tosilate. Suplatast
tosilate was considered useful as a baseline drug for
the treatment of allergic rhinitis.
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